Newron Pharmaceuticals S.p.A.
Stock Forecast, Prediction & Price Target
Newron Pharmaceuticals S.p.A. Financial Estimates
Newron Pharmaceuticals S.p.A. Revenue Estimates
Newron Pharmaceuticals S.p.A. EBITDA Estimates
Newron Pharmaceuticals S.p.A. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| CHF5.76M N/A | CHF6.09M 5.76% | CHF9.05M 48.62% | Avg: CHF26.00M Low: CHF8.16M High: CHF39.87M avg. 187.14% | Avg: CHF41.05M Low: CHF13.11M High: CHF64.05M avg. 57.84% | Avg: CHF117.42M Low: CHF37.52M High: CHF183.22M avg. 186.04% | Avg: CHF183.83M Low: CHF58.75M High: CHF286.85M avg. 56.55% |
Net Income
% change YoY
| CHF-14.90M N/A | CHF-17.49M -17.39% | CHF-16.22M 7.25% | Avg: CHF5.41M Low: CHF-69.65M High: CHF89.00M avg. 133.39% | Avg: CHF23.54M Low: CHF2.71M High: CHF40.70M avg. 334.65% | Avg: CHF62.05M Low: CHF7.16M High: CHF107.26M avg. 163.53% | Avg: CHF109.33M Low: CHF12.62M High: CHF188.98M avg. 76.19% |
EBITDA
% change YoY
| CHF-12.31M N/A | CHF-13.26M -7.75% | CHF-11.83M 10.81% | Avg: CHF-26.00M Low: CHF-39.87M High: CHF-8.16M avg. -119.81% | Avg: CHF-41.05M Low: CHF-64.05M High: CHF-13.11M avg. -57.84% | Avg: CHF-117.42M Low: CHF-183.22M High: CHF-37.52M avg. -186.04% | Avg: CHF-183.83M Low: CHF-286.85M High: CHF-58.75M avg. -56.55% |
EPS
% change YoY
| -$0.84 N/A | -$0.98 -16.66% | -$0.91 7.14% | Avg: $0.3 Low: -$3.9 High: $4.99 avg. 133.36% | Avg: $1.32 Low: $0.15 High: $2.28 avg. 334.65% | Avg: $3.48 Low: $0.4 High: $6.01 avg. 163.53% | Avg: $6.13 Low: $0.71 High: $10.59 avg. 76.19% |
Operating Expenses
% change YoY
| CHF17.78M N/A | CHF19.67M 10.64% | CHF20.68M 5.13% | Avg: CHF31.45M Low: CHF9.87M High: CHF48.23M avg. 52.05% | Avg: CHF49.64M Low: CHF15.86M High: CHF77.46M avg. 57.84% | Avg: CHF142.01M Low: CHF45.38M High: CHF221.59M avg. 186.04% | Avg: CHF222.33M Low: CHF71.05M High: CHF346.92M avg. 56.55% |
FAQ
What is Newron Pharmaceuticals S.p.A. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 176.94% in 2025-2028.
We have gathered data from 3 analysts. Their low estimate is -69.65M, average is 5.41M and high is 89.00M.
What is Newron Pharmaceuticals S.p.A. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 121.89% in 2025-2028.
We have gathered data from 3 analysts. Their low revenue estimate is CHF8.16M, average is CHF26.00M and high is CHF39.87M.
What is Newron Pharmaceuticals S.p.A. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 176.93% in 2025-2028.
We have gathered data from 3 analysts. Their low earnings per share estimate is -$3.9, average is $0.3 and high is CHF4.98.